Specific mutations compromising the primary structure of the FVIII protein, combined with distinct HLA profiles, may trigger aberrant antigen presentation and subsequent inhibitor formation in AHA patients [56,61]. This evidence concerns the gene F8 and autoimmune hemolytic anemia.